Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $269,173.38 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 2,274 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $118.37, for a total transaction of $269,173.38. Following the completion of the sale, the director now owns 519,074 shares of the company’s stock, valued at approximately $61,442,789.38. The trade was a 0.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Kevin Charles Gorman also recently made the following trade(s):

• On Thursday, February 13th, Kevin Charles Gorman sold 5,844 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36.
• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.92, for a total transaction of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $115.02 on Friday. The stock has a market cap of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. The firm’s 50-day moving average is $138.09 and its 200 day moving average is $130.82. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, equities analysts expect that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Bank of America decreased their target price on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Morgan Stanley boosted their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Piper Sandler reissued an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Finally, William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $166.90.

Hedge Funds Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of NBIX. Golden State Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $25,000. Huntington National Bank boosted its holdings in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after acquiring an additional 97 shares during the last quarter. Brooklyn Investment Group boosted its holdings in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the last quarter. GeoWealth Management LLC boosted its holdings in shares of Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after acquiring an additional 102 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.